The Effects of Heparin Bound Surface Modification (Carmeda<sup>®</sup> Bioactive Surface) on Human Platelet Alterations During Simulated Extracorporeal Circulation

Nina Stenach, Robert L. Korn, Carol A. Fisher, Valluvan Jeevanandam, V. Paul Addonizio

Journal of ExtraCorporeal Technology · 1992 · 11 citations · 19 references

DOIFull text

Open access

Concepts

Abstract

To determine if treatment with covalently bound heparin (Carmeda Bioactive Surface (CBAS)) a to the synthetic surface of the extracorporeal circuit (ECC) would alter the stereotypic pattern of adverse platelet alterations, 450 ml of heparinized blood (lU/ml) was recirculated at a flow rate of twice the circulating volume (L/min) for 2 hrs at 37°C through either untreated (CONT,n=7) or treated (CBAS,n=7)circuits constructed of identical components including a pediatric (0.8m 2 ) reversed hollow fiber membrane oxygenator. In CONT circuits, platelet count maintained 88+1% (x±SEM) of its initial level in the circuit prime sample, dropped to 36±6% after 5 min, and returned to 56±2% following 2 hrs of ECC. In CBAS circuits, platelet count in the circuit prime sample demonstrated 90±4%, decreased to 68±10% after 5 min (p&lt;0.05) and declined further to 45±5% after 2 hrs (NS). Although platelets from both groups retained reactivity to ADP after priming the circuit, only at 5 min of recirculation did CBAS circuits significantly preserve this responsiveness. In CONT circuits, baseline plasma levels of platelet factor 4 rose from 24±3 to 581±82 ng/ml in the primed circuit and continued to rise to 2933±27 6 ng/ml by 2 hrs of ECC. In contrast, CBAS circuits markedly reduced this release after 2 hrs (577±165 ng/ml). Furthermore, by 2 hrs of ECC, plasma levels of thromboxane B2 in the CBAS circuits were significantly reduced when compared to CONT circuits (3035±1529 vs 29916±16293 pg/ml, respectively). We conclude that CBAS modification of the simulated extracorporeal circuit preserved the initial circulating platelet count with retained ADP reactivity and markedly decreased release of platelet factor 4 and thromboxane B 2 .

References

19